ProCE Banner Activity

NASH Screening in Diabetes

Podcast Episodes
Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk.

Released: July 07, 2020

Expiration: July 06, 2021

Share

Faculty

Brent A. Neuschwander-Tetri

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Saint Louis University Liver Center
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri

Provided by

Provided by the American Gastroenterology Association.
ProCE Banner

Supporters

Supported by educational grants from

Allergan

Gilead

Intercept Pharmaceuticals

Partners

Endocrine Society

ProCE Banner

Faculty Disclosure

Primary Author

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Saint Louis University Liver Center
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri

Brent A. Neuschwander-Tetri, MD, has disclosed that he has received consulting fees from Allergan, Allysta, Arrowhead, ARTham, Axcella, Blade, Boehringer Ingelheim, Bristol-Myers Squibb, Coherus, Consynance, CymaBay, Durect, Enanta, Ferring, Fortress, Gelesis, Genfit, Gilead Sciences, HighTide, HistoIndex, Intercept, Lipocine, Llama, Madrigal, MedImmune, Merck, Metacrine, Mundipharma, NGM, pH-Pharma, Prometheus, and Siemens and funds for research support paid to Saint Louis University from Allergan, Bristol-Myers Squibb, Cirius, CymaBay, Enanta, Galectin, Genfit, Gilead Sciences, Intercept, Madrigal, NGM, and Prometheus.

Staff Disclosure

Staff

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.